EC approves Stivarga for mCRC

The European Commission approved Stivarga regorafenib from Bayer AG (Xetra:BAYN) to treat metastatic colorectal cancer (mCRC) in adults who have been previously treated with or who are not considered candidates for available therapies. The dual acting signal transduction (DAST) inhibitor is already approved in the U.S. to treat mCRC and locally advanced, unresectable or metastatic gastrointestinal stromal tumors (GIST), and in Japan to treat unresectable, advanced or recurrent colorectal cancer. ...